These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 28570672)
41. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Goodrich RP; Edrich RA; Li J; Seghatchian J Transfus Apher Sci; 2006 Aug; 35(1):5-17. PubMed ID: 16935562 [TBL] [Abstract][Full Text] [Related]
42. Recent insights into the mechanism of transfusion-related acute lung injury. Sachs UJ Curr Opin Hematol; 2011 Nov; 18(6):436-42. PubMed ID: 21912251 [TBL] [Abstract][Full Text] [Related]
43. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184 [TBL] [Abstract][Full Text] [Related]
44. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Tonnetti L; Proctor MC; Reddy HL; Goodrich RP; Leiby DA Transfusion; 2010 May; 50(5):1019-27. PubMed ID: 20030791 [TBL] [Abstract][Full Text] [Related]
45. The effect of storage on the accumulation of oxidative biomarkers in donated packed red blood cells. Rael LT; Bar-Or R; Ambruso DR; Mains CW; Slone DS; Craun ML; Bar-Or D J Trauma; 2009 Jan; 66(1):76-81. PubMed ID: 19131808 [TBL] [Abstract][Full Text] [Related]
46. Antibody-mediated transfusion-related acute lung injury; from discovery to prevention. Peters AL; Van Stein D; Vlaar AP Br J Haematol; 2015 Sep; 170(5):597-614. PubMed ID: 25921271 [TBL] [Abstract][Full Text] [Related]
48. Pathogen reduction treatment alters the immunomodulatory capacity of buffy coat-derived platelet concentrates. Loh YS; Johnson L; Kwok M; Marks DC Transfusion; 2014 Mar; 54(3):577-84. PubMed ID: 23829895 [TBL] [Abstract][Full Text] [Related]
49. Transfusion-related acute lung injury and potential risk factors among the inpatient US elderly as recorded in Medicare claims data, during 2007 through 2011. Menis M; Anderson SA; Forshee RA; McKean S; Johnson C; Warnock R; Gondalia R; Mintz PD; Holness L; Worrall CM; Kelman JA; Izurieta HS Transfusion; 2014 Sep; 54(9):2182-93. PubMed ID: 24673344 [TBL] [Abstract][Full Text] [Related]
51. Pathogenesis of non-antibody mediated transfusion-related acute lung injury from bench to bedside. Peters AL; van Hezel ME; Juffermans NP; Vlaar AP Blood Rev; 2015 Jan; 29(1):51-61. PubMed ID: 25277811 [TBL] [Abstract][Full Text] [Related]
52. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Vanlandingham DL; Keil SD; Horne KM; Pyles R; Goodrich RP; Higgs S Transfusion; 2013 Feb; 53(2):284-90. PubMed ID: 22626525 [TBL] [Abstract][Full Text] [Related]
53. Mirasol PRT system inactivation efficacy evaluated in platelet concentrates by bacteria-contamination model. Jocić M; Trkuljić M; Jovicić D; Borovcanin N; Todorović M; Balint B Vojnosanit Pregl; 2011 Dec; 68(12):1041-6. PubMed ID: 22352265 [TBL] [Abstract][Full Text] [Related]
54. Transfusion-related acute lung injury: Current understanding and preventive strategies. Vlaar AP Transfus Clin Biol; 2012 Jun; 19(3):117-24. PubMed ID: 22682310 [TBL] [Abstract][Full Text] [Related]
55. A threshold model for the susceptibility to transfusion-related acute lung injury. Sachs UJ Transfus Clin Biol; 2012 Jun; 19(3):109-16. PubMed ID: 22677431 [TBL] [Abstract][Full Text] [Related]
56. Transfusion therapy and acute lung injury. Sokolovic M; Pastores SM Expert Rev Respir Med; 2010 Jun; 4(3):387-93. PubMed ID: 20524921 [TBL] [Abstract][Full Text] [Related]
57. Transfusion-related lung injury in children: a case series and review of the literature. Lieberman L; Petraszko T; Yi QL; Hannach B; Skeate R Transfusion; 2014 Jan; 54(1):57-64. PubMed ID: 23763359 [TBL] [Abstract][Full Text] [Related]
58. Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment--a comparative study. Balint B; Jovicic-Gojkov D; Todorovic-Balint M; Subota V; Pavlovic M; Goodrich R Transfus Apher Sci; 2013 Dec; 49(3):434-9. PubMed ID: 23820430 [TBL] [Abstract][Full Text] [Related]
59. Pathogen-reduction systems for blood components: the current position and future trends. Seghatchian J; de Sousa G Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168 [TBL] [Abstract][Full Text] [Related]
60. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Ambruso DR; Thurman G; Marschner S; Goodrich RP Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]